No Data
No Data
Volume change rate ranking (13:00) - JANO ME, NICHIRIN, etc. are ranked.
In the volume change rate ranking, you can understand the market participants' interest in trends and other hunting based on the comparison between the average volume of the past 5 days and the volume on the delivery date. ■ Volume change rate top [As of 13:32 on August 23] (Comparison of average volume of the past 5 days) Code ⇒ Stock ⇒ Volume ⇒ 5-day average volume ⇒ Volume change ratio ⇒ Stock price change ratio <2134> Kitahama Capital 8761200 38231.36 163.91% 0.0526% <2329> East
Emerging market stock digest: Daijigestu BlueMeme has significantly risen for 4 consecutive days, while Digipura has hit the limit high.
<4069> BlueMeme has risen significantly for the 4th day in a row, up 1130 points (+127). They have announced the implementation of a share buyback of up to 0.1 million shares (¥0.1 billion). The percentage of outstanding shares (excluding treasury shares) is approximately 2.8%. The acquisition period is from 21st day to August 20th 25. The goal is to enable flexible capital policy in response to changes in the business environment. In addition to the favorable response of the share buyback as a shareholder return strategy, the stock price is above the 25-day and 75-day moving averages.
Volume change rate ranking (13:00) - Doricom, Piala, etc. are ranked
In the volume change rate ranking, you can understand the interest of market participants such as the trend of trading by comparing the average volume for the past 5 days with the volume on the delivery day. Top volume change rate [August 21, 13:32 current] (comparing average volume for the past 5 days) Code ⇒ Stock ⇒ Volume ⇒ 5-day average volume ⇒ Volume change rate ⇒ Stock price change rate <7616> Coloride 3995500 522640.2 287.11% -0.098% <2410> Ki
Stellapharma - significant 4-day consecutive increase, applying for orphan drug designation for SPM-011 for relapsed malignant glioma, etc.
It has been announced that it has applied for orphan drug designation for boropharan (10B) (SPM-011), which is being developed as a boron drug for BNCT (boron neutron capture therapy), targeting recurrent malignant gliomas and recurrent meningiomas, to the Ministry of Health, Labor and Welfare. Orphan drug designation is a system that promotes research and development of pharmaceuticals for rare diseases, and if designated, it will receive preferential treatment such as subsidies for research and development costs from the government.
Light Up, Stella Pharma, and others.
<4258> NTT Communications, which handles the ICT service and solutions business, etc., has signed a sales agency agreement with dealers. <4596> Kubota Pharmaceutical HD's 33rd new share subscription rights (with a exercise price modification clause issued (14 million potential shares, procurement amount of approximately 0.972 billion yen) <4888> Stella Pharma Borofaran (10B) (SPM-011) applies for orphan drug designation for recurrent malignant gliomas and recurrent meningomas. <5129> FIXER downward revision.
Stella Pharma: Supplementary materials for the first quarter financial results of the March 2025 period.
No Data